Found Weight Loss: BBB Ratings, Consumer Complaint Trends, and an Independent Look at Legitimacy

What Is Found and How Does Its Clinical Model Work?

Found operates as an asynchronous and synchronous telehealth platform focused on medically supervised weight management. Clinicians on the platform can prescribe FDA-approved anti-obesity agents and certain off-label medications after an intake assessment. The platform does not require in-person visits.

The Medication Menu

Found's formulary includes semaglutide (brand names Wegovy and Ozempic), tirzepatide (brand names Zepbound and Mounjaro), and several older agents: naltrexone/bupropion (Contrave), topiramate, and metformin. Semaglutide 2.4 mg (Wegovy) carried the first dedicated FDA approval for chronic weight management in adults with a BMI of 30 or with a BMI of 27 accompanied by at least one weight-related comorbidity. [1] Tirzepatide 2.5 to 15 mg (Zepbound) received its own FDA obesity approval in November 2023. [2]

The STEP-1 and SURMOUNT-1 Clinical Basis

The prescriptions Found clinicians write are grounded in real trial data. STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body-weight reduction at 68 weeks versus 2.4% for placebo (P<0.001). [3] SURMOUNT-1 (N=2,539) demonstrated that tirzepatide 15 mg produced 20.9% mean body-weight reduction at 72 weeks versus 3.1% for placebo. [4] Those numbers represent the ceiling, not a guaranteed result for any individual patient. Found's marketing tends to cite these aggregate figures without always contextualizing the dropout rates or the need for ongoing medication adherence.

Non-GLP-1 Prescribing

For patients who do not qualify for or cannot afford GLP-1 agents, Found prescribes combinations such as naltrexone/bupropion (Contrave), which the FDA approved in 2014 for chronic weight management. [5] The average weight loss with Contrave is approximately 4.8% from baseline at 56 weeks compared with 1.4% for placebo, per the COR-I trial (N=1,742). [6] That figure sits well below the GLP-1 benchmarks above. A transparent prescriber should communicate this difference clearly.

Found's BBB Profile: What the Data Actually Show

The Better Business Bureau is not a medical or regulatory body. Its ratings reflect complaint volume relative to business size, complaint resolution patterns, and whether a company responds. BBB accreditation means a business has paid membership fees and agreed to the BBB's code of conduct. It does not certify clinical quality.

Accreditation vs. Customer Reviews

Found holds BBB accreditation. However, accreditation and customer review scores are separate metrics. Consumer-submitted star ratings on the BBB site have historically trended below 2 out of 5 for Found, based on reviews accessible through the BBB's public portal. That gap between formal accreditation and low consumer ratings is itself informative. Accreditation reflects responsiveness to complaints; reviews reflect patient experience.

Complaint Categories

A review of the complaint categories on Found's BBB profile reveals three recurring themes:

• Billing and unauthorized charges. Patients report being charged after attempting to cancel, or charged for medication tiers they did not select.
• Subscription cancellation difficulty. Multiple complaints describe a cancellation process requiring phone calls or extended email chains rather than a simple online toggle.
• Medication fulfillment delays. Patients report delays between prescription approval and medication shipment, sometimes running four to six weeks.

These categories are not unique to Found. Noom, Ro, and Hims/Hers carry similar BBB complaint patterns. The pattern does, however, suggest that Found's billing and operations infrastructure has not kept pace with subscriber growth.

BBB Complaint Resolution Rate

The BBB tracks whether companies respond to and resolve filed complaints. Found's documented response rate has been relatively high, meaning most complaints receive a company reply. Resolution, though, does not always mean the consumer's preferred outcome. A refund offered as store credit, for example, counts as "resolved" in the BBB system even if the consumer wanted cash back.

Regulatory Standing: FDA, LegitScript, and State Boards

FDA and Compounded Semaglutide

Found, like many GLP-1 telehealth platforms, offered compounded semaglutide during the period when the FDA listed semaglutide on its drug shortage list. In March 2024, the FDA removed semaglutide from that shortage list, which changed the legal field for 503A and 503B compounding pharmacies dispensing semaglutide copies. [7] The FDA issued guidance stating that once a drug exits shortage status, most compounding of that drug no longer qualifies under the statutory exemptions. [7] Patients currently receiving compounded semaglutide through Found or any other platform should confirm the current compounding status with their dispensing pharmacy directly.

LegitScript Certification

LegitScript is an independent pharmacy verification service used by Google and other platforms to vet online pharmacies and telehealth companies. Patients evaluating any telehealth prescriber, including Found, should check LegitScript's database at legitscript.com before providing payment information. LegitScript certification does not guarantee clinical quality but does confirm that the entity is operating within basic pharmacy law standards.

State Medical Board Oversight

Telehealth prescribing is regulated at the state level by individual medical and pharmacy boards. No confirmed, publicly available state medical board disciplinary action against Found or its contracted clinicians was identified as of mid-2025. That absence of a public record is reassuring but not a clean bill of health. State board records are not always centralized or rapidly updated.

Is Found Legit? An Independent Clinical Assessment

The word "legit" carries at least three separate meanings in this context: legally operating, clinically sound, and financially fair. Found scores differently on each dimension.

Legal Operations

Found appears to operate within the applicable telehealth prescribing frameworks in the states where it offers services. Its prescribers hold state licensure, and its affiliated pharmacies are licensed dispensers. The platform does not appear on FDA warning-letter lists or FTC enforcement actions as of this writing.

Clinical Soundness

The medications Found prescribes have real FDA approvals and real trial evidence behind them (see STEP-1 and SURMOUNT-1 data above). The clinical concern is not the drugs themselves but the depth of ongoing clinical oversight. Asynchronous telehealth models, where patients exchange messages rather than speaking directly with a clinician, carry inherent limitations for monitoring side effects such as gastroparesis, pancreatitis, or the thyroid C-cell concerns noted in the semaglutide prescribing information. [1] The Endocrine Society's 2023 Clinical Practice Guideline on obesity pharmacotherapy states: "Anti-obesity medications require ongoing monitoring of efficacy, tolerability, and safety, and the treating clinician should have direct communication with the patient at a frequency appropriate to the medication's risk profile." [8]

Financial Fairness

This is where Found draws the most consumer criticism. Subscription models that bundle clinical visits with medication access create misaligned incentives. If a patient decides to pause medication, the subscription fee may continue. Patients have reported difficulty extracting themselves from billing cycles even after formal cancellation requests, as documented in the BBB complaint log. Before subscribing, patients should read the cancellation policy in the terms of service, specifically the clause governing billing cycles after a cancellation request is submitted.

How Found Compares With Other GLP-1 Telehealth Platforms

Ro, Hims/Hers, Calibrate, and WeightWatchers (which acquired a telehealth prescribing model) all occupy the same competitive space. Each has its own complaint profile.

Pricing Transparency

Found's pricing is not always fully transparent at the start of the signup funnel. The base membership fee does not include medication costs, and GLP-1 medications represent a substantial separate expense. Branded Wegovy has a list price above $1,300 per month without insurance. [1] Generic naltrexone/bupropion costs considerably less. Patients need to see the total cost, including medication, before committing.

BCBS Partnerships

Found has announced Blue Cross Blue Shield network agreements in select states, which may allow some members to use insurance benefits toward the consultation fee or, in some cases, toward the medication itself. Coverage for anti-obesity medications remains inconsistent. As of 2024, fewer than 40% of commercial health plans covered GLP-1 medications for obesity rather than only for type 2 diabetes, per American Diabetes Association position statements. [9] A patient should call their insurer directly rather than relying on any platform's coverage claims.

Clinical Supervision Depth

Calibrate requires quarterly video visits with a physician. Found's model is more asynchronous. Neither model matches the clinical intensity of an in-person obesity medicine specialist. For patients with BMI <35 and uncomplicated metabolic profiles, the asynchronous model may carry acceptable risk. For patients with prior pancreatitis, a personal or family history of medullary thyroid carcinoma, or multiple comorbidities, a higher level of clinical supervision is appropriate before starting a GLP-1 agent. [1] [8]

Red Flags and Green Flags: A Practical Checklist

Red Flags to Watch

• Difficulty finding the cancellation process before signing up
• Compounded semaglutide offered without disclosure of current FDA shortage-list status
• No clear pathway to speak with a licensed clinician by phone or video
• Total monthly cost (subscription plus medication) not disclosed upfront
• Pressure to prepay for three or more months before a clinical assessment is complete

Green Flags That Suggest a More Trustworthy Interaction

• Clinician licensed in your state is named before payment
• Labs (HbA1c, lipid panel, thyroid function) are ordered or reviewed before GLP-1 initiation
• Side-effect monitoring protocol is described in writing
• Clear refund policy for unused medication
• LegitScript certification is current

What Patients Should Do Before Signing Up With Found

A telehealth weight-loss platform is appropriate for some patients and not for others. The American Association of Clinical Endocrinology 2022 consensus on obesity states that comprehensive obesity management should include behavioral, nutritional, and pharmacological components, with intensity calibrated to the degree of excess weight and metabolic risk. [10]

Step One: Confirm Your Clinical Eligibility

FDA-approved anti-obesity pharmacotherapy is indicated for adults with BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. [1] [2] Patients below those thresholds using these medications are using them off-label.

Step Two: Verify Your Insurer's Coverage Before Paying Out-of-Pocket

Call your insurance member services line and ask specifically whether GLP-1 medications prescribed for obesity (not only for type 2 diabetes) are covered under your current plan year. Ask for the prior authorization criteria. Then ask whether Found's affiliated clinicians are in-network.

Step Three: Read the Cancellation Terms

Found's terms of service are publicly available. Before entering payment information, scroll to the section governing subscription termination and billing cycles. Note the number of days' notice required and whether a cancellation submitted on day 31 of a 30-day cycle triggers a new full charge.

Step Four: Document Everything

Save confirmation emails, prescription communications, and cancellation requests with timestamps. If a billing dispute arises, this documentation supports a chargeback request through your credit card issuer under Fair Credit Billing Act protections.

The Clinical Bottom Line

Found prescribes real medications with real evidence behind them. The complaint pattern documented on the BBB and across consumer review platforms is primarily operational and financial, not clinical. That distinction matters. A patient who gets a legitimate semaglutide prescription filled at a licensed pharmacy but then struggles to cancel a subscription has a billing problem, not a medical harm. However, billing problems that delay or disrupt medication access become clinical problems. A patient who cancels because of a billing dispute and stops semaglutide abruptly should be aware that STEP-1 extension data show most of the weight lost during active treatment is regained within one year of discontinuation. [11]

Patients considering Found should weigh that operational track record against the genuine clinical benefit of the medications it can prescribe, confirm their eligibility by current FDA-approved criteria, and review cancellation terms before paying. If a patient's BMI and comorbidity profile warrant GLP-1 therapy, a found prescription may be clinically appropriate. An obesity medicine specialist or endocrinologist remains the highest standard of care for complex cases.